In March 2024, the US Food and Drug Administration (FDA) granted accelerated approval to Rezdiffraâ„¢ (resmetirom) in conjunction with diet and exercise for the treatment of adults with noncirrhotic ...
Rezdiffra (resmetirom) is a prescription drug used to treat certain types of nonalcoholic steatohepatitis (NASH). Rezdiffra can cause side effects that range from mild to serious, such as diarrhea and ...